Ann: Application for quotation of securities - CHM, page-41

I don't have any issue with Jason Litten (per se) either... just as I didn't have any issue with Jennifer Chow, other than the ongoing cost to CHM. I agree that his intrinsic value is in the trials necessary to confirm the potential of our pipeline of therapies. A CMO (of calibre) based in the US is a necessity while we continue to trial therapies in the US and with founding collaborators. But ongoing costs are proving to be an issue. What we need is for CORE-NK to start generating interest beyond the investigators running the trials. Revenue from grants and licensing deals is needed at this juncture in parallel with cornerstone investment. That could readily happen with near-term data readouts.